Continuous decrease in plasma VEGF-A levels, from baseline to day 14 of treatment, was previously correlated with prolonged PFS in patients with advanced NSCLC receiving chemotherapy-ICI combination therapy, suggesting the potential predictive value of this marker [49]. Here, VEGFA is linked to non-small cell lung carcinoma.